Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS

Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, is delighted to announce that it is one of six organisations sharing $2.9 million in grants from the ALS Association that support the advancement of novel therapies for the treatment of amyotrophic lateral ...

Related Keywords

Paris ,France General ,France ,Lolita Petit ,Kuldip Dave ,Isabel Barnett Drug Development Program ,Linkedin ,Nuclear Fractions Of Alzheimer ,Association Lawrence ,Coave Therapeutics ,Isabel Barnett Drug Development ,Senior Vice President ,Cell Sci ,Selectively Reduced ,Nuclear Fractions ,Amyotrophic Lateral Sclerosis ,Trehalose Reduces Accumulation ,Cell Model ,Neurotox Res ,Advanced Vectors Ligand Conjugates ,Lipid Nanoparticles ,